In Brief
Epigenetic crosstalk targeting together with MLL1-based stratification and inhibiting feedback MAPK activation expand EZH2 inhibitors' therapeutic utility and efficacy in patient-derived solid tumor models.
Mutations or aberrant upregulation of EZH2 occur frequently in human cancers, yet clinical benefits of EZH2 inhibitor (EZH2i) remain unsatisfactory and limited to certain hematological malignancies. We profile global posttranslational histone modification changes across a large panel of cancer cell lines with various sensitivities to EZH2i. We report here oncogenic transcriptional reprogramming mediated by MLL1's interaction with the p300/CBP complex, which directs H3K27me loss to reciprocal H3K27ac gain and restricts EZH2i response. Concurrent inhibition of H3K27me and H3K27ac results in transcriptional repression and MAPK pathway dependency in cancer subsets. In preclinical models encompassing a broad spectrum of EZH2-aberrant solid tumors, a combination of EZH2 and BRD4 inhibitors, or a triple-combination including MAPK inhibition display robust efficacy with very tolerable toxicity. Our results suggest an attractive precision treatment strategy for EZH2-aberrant tumors on the basis of tumor-intrinsic MLL1 expression and concurrent inhibition of epigenetic crosstalk and feedback MAPK activation.
INTRODUCTION
Enzymatic inhibition of EZH2, the enzymatic subunit of the polycomb repressive complex 2 (PRC2) that plays a pivotal role in catalyzing the methylation of the lysine 27 of histone H3 (H3K27), has been intensively explored as cancer therapy. Two leading compounds, EPZ-6438 and GSK126, demonstrate preliminary benefits in a small subset of hematological malignances, including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (Kurmasheva et al., 2017; Lee et al., 2014; McCabe et al., 2012b) bearing EZH2 gene mutations. EZH2 mutations result in constitutively activated EZH2 enzymatic activity and are believed to drive a H3K27 methylation (H3K27me)-dependent cell growth resembling well-defined oncogenic drivers (Brach et al., 2017; Huet et al., 2017; McCabe et al., 2012a; Morin et al., 2010) . However, EZH2 mutations occur in a very small subset of hematological tumors. In most solid tumors, EZH2 is present in an overexpressed wild-type form that similarly bears H3K27me catalyzing activity. It remains unclear, however, whether overexpressed wild-type EZH2 could also functionally result in growth dependency of H3K27me. Insights in this regard may expand the therapeutic benefits of EZH2 inhibitors (EZH2is) to a broad spectrum of solid tumors (Bachmann et al., 2006; Bracken et al., 2003; Kim and Roberts, 2016; McCabe et al., 2012b; Sun et al., 2016; Varambally et al., 2002) .
Recent efforts have also tried to identify cancer subsets that are exquisitely responsive to EZH2i apart from those bearing EZH2 gene mutation (Knutson et al., 2012) . The dysfunction of SWI-SNF complex, a chromatin-remodeling regulator that partially antagonizes the catalytic function of PRC2 complex, has been demonstrated to sensitize cancer cells to EZH2i treatment both in vitro and in vivo; loss of function of the components of the SWI-SNF complex-mainly BRG1, Arid1A, SMARCA4, or INI1-renders cancer cells from several solid tumor types' responsiveness to EZH2is in vitro and in vivo (Bitler et al., 2015; Fillmore et al., 2015; Kim et. al (2015) ; Zhang et al., 2014) . PRC2 also antagonizes the histone modification of demethylase JMJD3/UTX and transcriptionally regulates the TrxG and p300/ CBP complexes. However, it remains unclear how these opposing complexes cooperatively maintain the intrinsic balance of epigenetic modulations and whether the interaction between these complexes and related histone modifications are important to the response to EZH2i.
In this study, we utilize an integrative and large-scale approach to address how EZH2i modulates global epigenetic signatures and, more importantly, how the new insights can be (A) Histone modification analysis. The fold change of global histone posttranslational modifications in six cancer cell lines (from insensitive to sensitive cell lines, 1-6: U2932, SMMC-7721, T47D, SU-DHL-4, KARPAS-422, and Pfeiffer) in EPZ-6438-treated cells compared with DMSO-treated cells was detected by SILAC-based mass spectrometry. The darkest blue or red indicates four-or-more-fold change. The blank indicates no change or not applicable (N/A). (B) Principal-component analysis (PCA). The cell lines with different EPZ-6438 sensitivity were analyzed by PCA based on the histone-modification quantification ratios of cells in (A) . (C) Association between H3K27ac activation versus EPZ-6438 sensitivity in cancer cells. Cells were treated with EPZ-6438 at gradient concentrations for 6 days and IC 50 s measured using SRB assay or CCK-8 assay. H3K27ac was detected by immunoblotting. Left vertical axis: IC 50 s of different cancer cell lines. Right vertical axis: the H3K27ac level ratio of EPZ-6438 versus control group. Horizontal axis: different cancer cell lines. translated into a better therapeutic strategy using EZH2is in a variety of solid tumors.
RESULTS

H3K27 Acetylation Upregulation Is Associated with the Resistance to EZH2 Inhibition
To gain a more systematic understanding of cellular response to EZH2 inhibition in human cancers, we first probed the cell sensitivity to EZH2i using a panel of 83 cancer cell lines derived from different cancer types across solid and hematological tumors, most of which exhibited high level of EZH2 expression (Figure S1A) . EPZ-6438 and GSK126, two well-validated EZH2is under clinical development, were used to measure the cell sensitivity toward EZH2 inhibition. As expected, hematologic tumor cell lines were generally more sensitive to EZH2is. 11 out of 20 hematological cancer cell lines showed IC 50 s (half-maximal inhibitory concentration) below 1 mM, while solid tumor cell lines were relatively less sensitive ( Figure S1B and Table S1 ). This observation was also confirmed using two independent EZH2 siRNAs. In spite of the similarly abolished H3K27me in these cancer cells, the majority of cancer cells did not exhibit apparent growth inhibition ( Figure S1C ).
EZH2 and the PRC2 complex are mostly known for their essential roles in regulating epigenetic signatures-particularly H3K27me (Di Croce and Helin, 2013) . We compared the impact of EZH2i on the pattern of global posttranslational histone modifications between the sensitive and insensitive lines. Systematic quantitative analysis of histone modification changes was examined using stable isotope labeling with amino acids in cell culture (SILAC)-based mass spectrometry analysis. In total, we identified 111 histone marks belonging to 13 types of histone modifications ( Figure 1A and Table S2 ). Upon EZH2i, a broad spectrum of histone marks was changed in both sensitive and insensitive (U2932, SMMC-7721, T47D and SU-DHL-4 cells) cell lines. While the H3K27 tri-methylation (H3K27me3) levels were similarly decreased in all the tested cells, a group of histone modifications were differentially affected between the sensitive and insensitive cells ( Figure 1A ). Among them, H3K27 acetylation (H3K27ac) level, which was marginally deceased or unchanged in the sensitive cells, was dramatically increased in the insensitive cells ( Figures 1A and 1B) . Moreover, knockdown of the SUZ12 subunit of the PRC2 complex or using an EED-targeted inhibitor could similarly induce H3K27ac upregulation, suggesting a PRC2 complex-dependent function ( Figure S1D ).
To further determine whether the feedback increase of H3K27ac may be associated with the response to EZH2i, we examined the alteration of H3K27ac in 43 representative cancer cell lines; IC 50 s of EPZ-6438 in these cell lines covered a wide range from 4 nM to 100 mM. Overall, cell sensitivity to EZH2i was closely associated with a reciprocal alteration of H3K27ac; those with higher level of H3K27ac after drug treatment tended to be more resistant to EZH2is ( Figures 1C-1E ). This finding was recapitulated in vivo in xenograft models ( Figure S1E ). Interestingly, in cancer cells with SWI/SNF or BAP1 mutation (LaFave et al., 2015; Schoumacher et al., 2016) , the increase of H3K27ac was also associated with the resistance to EPZ-6438 treatment ( Figure S1F ).
These results show that a reciprocal H3K27ac alteration is associated with cell responsiveness to EZH2 inhibition, suggesting that H3K27ac upregulation may contribute to the resistance to EZH2 inhibition.
MLL1 Facilitates p300-Catalyzed H3K27ac Elevation
A crosstalk between H3K27me and H3K27ac has been reported in embryonic stem (ES) cells (Ferrari et al., 2014; Pasini et al., 2010) , but the underlying mechanism is largely unknown. H3K27ac is known to be catalyzed by the p300/CBP complex. Therefore, we impaired the function of p300 complex using siRNAs against p300 or/and its binding partner, CBP. Deficiency in p300 and CBP almost completely reversed the EPZ-6438-induced H3K27ac accumulation (Figures 2A and S2A ). A similar result was obtained using C646 or SGC-CBP30, two inhibitors targeting the p300/CBP complex (Figures 2B and S2B) . Further, p300 intervention sensitized the resistant cells to EZH2i ( Figures S2C and S2D ). These results suggested that the reciprocal H3K27ac upregulation could be p300 driven.
It is noteworthy that the responsive cells exhibited a similar level of p300 as the resistant cells. It is puzzling why H3K27me loss, which is expected to increase the accessibility of p300 to the H3K27 residue, only causes the increase of H3K27ac in the resistant cells. p300 is known to require the proper recruitment to the histone tail by its binding partners, such as CBP, MLL family, UTX, CBX2, and CBX6 proteins (Choi et al., 2016; Lai et al., 2017; Vincenz and Kerppola, 2008; Wang et al., 2017) , and mass spectrometry analysis for p300 binding proteins revealed that less CBP bound to p300 in the sensitive cells (Table S3) . We suspected that there might be other p300 binding partners involved in allowing a H3K27me-H3K27ac feedback exchange. We therefore examined the expression level of suggested p300 binding partners across different cancer cell lines. Interestingly, the intrinsic expression level of UTX, DUX4, CBX2, CBX6, etc. appeared quite variable ( Figure S2E ). Among the tested proteins, MLL1 expression was strikingly different between the sensitive and insensitive cells, which appeared to be correlated with the H3K27ac response to EZH2i ( Figure 2C ). We also discovered that the interaction between p300 and CBP was affected by MLL1 knockdown ( Figure 2D ). In addition, MLL1, p300, and CBP formed a complex that the intervention of either component disrupted their interactions ( Figure S2F ).
More importantly, knockdown of MLL1 decreased the intrinsic H3K27ac level and reversed the feedback increase of H3K27ac induced by the treatment of EZH2is ( Figures 2E and S2G) , suggesting an essential role of MLL1 in facilitating p300-catalyzed H3K27ac. Consistently, MLL1 intervention sensitized the resistant cells to EZH2i (Figures 2F and S2H) . In agreement with these results, reconstitution of MLL1 increased the H3K27ac after EZH2 inhibition and impaired the cellular response to the treatment of EZH2i (Figures 2G and S2I) . This explained the lack of H3K27ac increase in Pfeiffer, KARPAS-422, and WSU-DL-CL2 cells, in which the expression of MLL1 was hardly detected ( Figure 2H ).
These data together suggested that p300 catalyzed H3K27ac upregulation upon EZH2i, and this process required 
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Histone H3 Figure 3A and Table S4 ). A more detailed comparison of the enriched oncogenic signatures between the insensitive U2932 and sensitive Pfeiffer cells were shown in Figure S3A .
We next compared the significantly enriched oncogenic signatures between the two insensitive cell lines U2932 and SMMC-7721. The result showed that 53 and 22 common oncogenic signatures were enriched in RNA-seq data and proteome data ( Figures 3B and 3C ), respectively. For example, KRAS.300_UP.V1_UP and MEK_UP.V1_UP were statistically enriched in both the RNA-seq data and the proteome data (Table S4 ). In addition, some oncogenic signatures were only enriched in certain cancer cell lines. For example, 101 and 12 unique signatures from the RNA-seq were statistically enriched in U2932 and SMMC-7721 ( Figure 3B ), respectively. In the proteome data, 42 and 23 unique signatures were enriched in U2932 and SMMC-7721 cells ( Figure 3C ), respectively.
In these two insensitive cell lines, some representative oncogenic signatures, such as MYC_UP.V1_UP, MEK_UP.V1_UP, were statistically enriched in the U2932 cell line, and KRA-S.50_UP.V1_UP, WNT_UP.V1_UP were statistically enriched in the SMMC-7721 cell line ( Figures 3D-3F and S3B-S3D). Notably, some oncogenes' promoter regions were enriched with H3K27ac, and these regions also showed increased binding of MLL1 and p300 ( Figure S3E ). This is consistent with MLL1-induced p300/CBP function accumulation.
Among oncogenic signatures, Wnt signaling pathway was noted for its well-validated roles in hepatocellular carcinoma (HCC) development (Cancer Genome Atlas Research Network, 2017; Monga, 2015) . We used it as a representative model to demonstrate the linkage between H3K27ac modification and pathway activations. ChIP-seq analysis in SMMC-7721 cells using H3K27ac antibody identified the increase of H3K27ac in the TSS region of CTNNB1 gene (which encodes b-catenin), a key component of Wnt pathway, after EZH2 inhibition ( Figure 3G ). The result was confirmed by ChIP-qPCR analysis using primers covering six regions of CTNNB1 promoter. In parallel to the decrease in the methylation level, H3K27ac level in these regions was significantly increased by EZH2i ( Figure S3F ). Accordingly, we detected about a 5-fold increase of mRNA level of CTNNB1 ( Figure 3H ), as well as the protein level increase upon EZH2 inhibition ( Figures 3I and S3G) . The functional activation of Wnt pathway by EZH2i was also confirmed using a TCF luciferase reporter assay ( Figure 3J ). Further, application of BRD4 inhibitor that impaired H3K27ac-medicated transcription could largely reverse b-catenin increase upon EZH2i ( Figure 3K ), suggesting that EZH2 inhibition increased H3K27ac caused Wnt pathway activation.
Together, these results demonstrated that H3K27ac upregulation due to EZH2 inhibition results in the transcriptional activation of multiple onco-pathways in a cell-context-dependent manner, which may underline the resistance to EZH2i.
Intervention of H3K27 Acetylation Sensitizes Cancer Cells to EZH2i
To demonstrate whether H3K27ac intervention could overcome resistance to EZH2i, we tested the therapeutic outcome of combining BRD4 inhibitor, which interferes with H3K27ac recognition (Filippakopoulos and Knapp, 2014; Wang and Filippakopoulos, 2015) , and EZH2i in various cell contexts. The combination with BRD4 inhibitor (EZH2-BRD4 inhibitor combo) significantly improved the efficacy of EPZ-6438 in over 11 cell lines across hematological and solid tumors. Measurement of combination index (CI) values clearly indicated the synergistic effect between EPZ-6438 and JQ1 in 11 resistant cell lines ( Figures 4A and S4A) .
We next expanded our study to xenograft models to confirm this therapeutic potential in vivo. In the U2932 xenograft model, daily single treatment with EPZ-6438 at up to 200 mg/kg had marginable therapeutic effect with tumor (B) and proteome data (C) , respectively. (D-F) Oncogenic signature enrichment plots (using oncogenic ''c6'' from the MSigDB) in H3K27ac ChIP-seq (D), RNA-seq (E) , and proteome (F) data with EPZ-6438 treatment versus DMSO treatment in the U2932 and SMMC-7721 cell lines. Plots indicate a significant (FDR q < 0.05) enrichment of oncogenic signatures after EPZ-6438 treatment. (G) Genomic snapshots of ChIP-seq experiments with H3K27ac antibody. SMMC-7721 cells were treated with EPZ-6438 (1 mM) for 6 days. (H) CTNNB1 mRNA level change. Cells treated as in (G) were subjected to qRT-PCR assay. mRNA fold level change was obtained as normalized by that of the untreated group. n = 3 replicates. (I) b-catenin protein level change. Cells were treated with EPZ-6438 (1 mM) or GSK126 (1 mM) for 6 days. Protein levels were analyzed by immunoblotting. (J) TCF transcriptional activity. Cells were transfected with TCF/LEF1 luciferase reporter constructs for 48 hr following pretreatment with EPZ-6438 for 4 days. Luciferase activity was normalized by that of the vehicle group. n = 4 replicates. (K) b-catenin protein level change. Cells were treated with EPZ-6438 (1 mM), JQ1 (0.25 mM) alone or combination for 6 days. Protein levels were analyzed by immunoblotting. Error bars represent mean ± SEM (H and J) analyzed by unpaired two-tailed t test. *p < 0.05, **p < 0.01, ***p < 0.001. NES, normalized enrichment score; P, nominal p value; Q, FDR q value; EPZ, EPZ-6438. See also Figure S3 and Table S4. growth inhibition (TGI) rate of less than 10%. Consistent with the findings above, analysis of intratumoral level of H3K27ac showed a remarkable increase of H3K27ac by EPZ-6438 treatment. In contrast, EZH2-BRD4 inhibitor combo significantly inhibited tumor growth, showing a TGI rate about 86.4% ( Figure 4B ).
We also tested the benefit of EZH2-BRD4 inhibitor combo in patient-derived xenograft ( T3  T2  T1  T3  T2  T1  T3  T2  T1  T3  T2  T1 EPZ + JQ1
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In two HCC PDX models, EPZ-6438 alone hardly inhibited tumor growth, largely recapitulating the clinical outcomes of EZH2-targeted therapy. EPZ-6438-stimulated increase of H3K27ac level in tumor tissues was similarly observed. Combinational treatment with EPZ-6438 and BRD4 inhibitor (OTX015) almost completely blocked tumor growth (Figures 4C and 4D) .
To further confirm these findings, we chose 12 cancer cell-line-derived xenograft (CDX) models (U2932, HCC1395, SMMC-7721, AsPC-1, NCI-H1299, NCI-H727, ZIP-177, PSN-1, BxPC-3, PC-9, NCI-H23, and NCI-H460) and 8 PDX models (7 HCC and 1 pancreatic) to test the therapeutic benefits of EZH2-BRD4 inhibitor combo (Figures 4E and S4B and  Table S7 ). In most models, introduction of BRD4 inhibitor substantially improved the therapeutic efficacy of EPZ-6438, in which the TGI ratio was increased by up to 104%. Among these models, 8 out 20 models showed significant response to EPZ-6438-JQ1 combo or EPZ-6438-OTX015 combo, with TGI rates over 60%. These results confirmed that a broad scope of cancers could benefit from EZH2-BRD4 inhibitor combo therapy irrespective of their diverse pathological or molecular subtypes. Importantly, immunohistochemical analysis of intratumoral level of MLL1 in these models observed the apparent difference between the EZH2i-responsive and EZH2i-non-responsive models. In the responsive Pfeiffer tumor, MLL1 level was almost undetectable ( Figure S4C ), confirming the role of MLL1 described above.
Blockage of H3K27 Acetylation Signal ContextDependently Activates MAPK Pathway According to our results, concurrent intervention of H3K27me and H3K27ac exhibited remarkable therapeutic promise but was still limited in a subset of cancers. Therefore, a quantitative mass-spectrometry-based proteomic analysis was conducted to compare the difference of significant oncogenic pathways enriched in U2932 and SMMC-7721 cells. The results showed that a variety of oncogenic pathways were statistically enriched in U2932 with EPZ-6438 treatment alone, but very few pathways were enriched in sample with EPZ-6438-JQ1 combo treatment. In contrast, in SMMC-7721 cell line, a significant percentage of oncogenic pathways was still enriched after EPZ-6438-JQ1 combo treatment compared to EPZ-6438 treatment alone ( Figure 5A and Table S5 ). These findings provided explanations for the differential response to EZH2-BRD4 combo treatment.
Notably, quite a few oncogenic pathways in SMMC-7721 cells upon EPZ-6438-JQ1 combo treatment were still enriched. Some of these pathways, such as KRAS.DF.V1_UP and AKT_UP.V1_UP, were involved in important phosphorylation signaling cascade ( Figure 5A and Table S5 ). This may indicate the crosstalk between epigenetic alteration and signaling kinase network (De Raedt et al., 2014; Nagaraja et al., 2017; Scott et al., 2016) . A phosphoproteome analysis was performed to compare U2932 and SMMC-7721 cells upon EPZ-6438 and JQ1 co-treatment. Indeed, KEGG-database-based enrichment analysis of the altered phosphoproteome revealed that multiple pathways-including FOXO, mTOR, MAPK, insulin, and ErbB signaling pathways-were differentially affected by EZH2-BRD4 inhibitor combo in the two cell lines (Figures 5B and S5A  and Table S6 ). Of particular note, the key phospho-sites in the MAPK pathway and their regulator proteins were differently regulated between U2932 and SMMC-7721 cells ( Figure S5B ), suggesting the activation of MAPK pathway in SMMC-7721 cells. We also constructed a phosphoprotome interaction network significantly regulated by EZH2-BRD4 inhibitor combo treatment in U2932 and SMMC-7721 ( Figures S5C and S5D ).
To understand how MAPK pathway was differentially affected, we examined the phosphorylation and protein expression levels of the major components in this pathway in a panel of cancer cells that showed different sensitivities to EZH2 mono-inhibition or EZH2-BRD4 inhibitor combo. Interestingly, in Pfeiffer and HT cells that were responsive to EZH2i, we observed the downregulated phospho-ERK in parallel with H3K27ac accumulation ( Figure S5E ). In contrast, in those insensitive to EZH2-BRD4 inhibitor combo, such as SMMC-7721, ZIP-177, and AsPC-1 cells, the phospho-ERK2, as well as its downstream effector protein phospho-RSK, was ubiquitously upregulated upon the treatment-strikingly different from the responsive cells, such as U2932 cells ( Figure 5C ).
Along with ERK2 activation, we also observed the decrease of ERK1 protein in all the insensitive cells ( Figure 5C ). ERK1 has been shown to antagonistically compete with ERK2 in binding to upstream MEK, and downregulation of ERK1 could result in the activation of ERK2 in a cell-context-dependent manner (Buscà et al., 2016; Fré min et al., 2007; Lefloch et al., 2008; Shin et al., 2010) . Depletion of ERK1-coding gene MAPK3 using two independent small interfering RNAs (siRNAs) led to the activation of ERK2 in SMMC-7721 and ZIP-177 cells ( Figure 5D ). Moreover, JQ1 or EZH2-BRD4 inhibitor combo decreased MAPK3 mRNA level in SMMC-7721 and ZIP-177 cells, suggesting a transcriptional downregulation of ERK1. In contrast, mRNA level of MAPK1, which encodes ERK2, was barely changed ( Figure 5E ). This result was further confirmed using BRD4 siRNA, which similarly decreased MAPK3 mRNA level without affecting MAPK1 ( Figure 5F ). Consistently, BRD4 siRNA per se could activate ERK2 ( Figure 5G ).
These data together suggest that intervention of H3K27ac may result in the feedback activation of MAPK signaling via transcriptional downregulation of ERK1 in subset of cancer cells.
Combined EZH2, BRD4, and ERK Inhibition Shows Striking Anticancer Effect in Solid Tumors BRD4-mediated feedback activation of ERK signaling suggests that blockage of MAPK would possibly further amplify the therapeutic benefit. This is supported by the pRSK status after EZH2-BRD4 inhibitor combo treatment, shown as an increase of pRSK in combo-resistant cell-line-dependent xenograft Cells treated with EPZ-6438 (2 mM) for 3 days were exposed to JQ1 (0.5 mM) alone or in combination for an extra 3 days. (D) Cells were transfected with either NC or MAPK3-siRNA for 3 days. Erk and RSK activation were examined by immunoblotting. (E and F) MAPK3 mRNA level alteration. (E) Cells pretreated with EPZ-6438 (2 mM) for 3 days were exposed to JQ1 (1 mM) treatment for an extra 24 hr. (F) Cells were transfected with either NC or BRD4-siRNA for 3 days. Samples were subjected to qRT-PCR assay. (G) MAPK3 protein level change. Cells were treated as in (F) , and proteins were detected by immunoblotting. Error bars represent mean ± SEM, n = 2 replicates for (E) and (F) . (E) and (F) analyzed by unpaired two-tailed t test, statistical comparisons are to control. *p < 0.05, **p < 0.01, ***p < 0.001. EPZ, EPZ-6438. See also Figure S5 and Tables S5 and S6. (CDX) or PDX models ( Figure 6A ). We therefore introduced an ERK1/2-specific inhibitor to the epigenetic-targeted combinational regimen.
In HCC PDX-0273 model, single treatment with EPZ-6438 or OTX015 showed only marginal effects on tumor growth (TGI%, À1.7% and 51.6%, respectively). Encouragingly, a triple combination of EPZ-6438, OTX015, and ERK1/2 inhibitor GDC-0994 almost completely suppressed tumor growth (TGI%, 99.1%) rather than EPZ-OTX015 combo therapy (TGI%, 67.0%) (Figures 6B and S6A) . Blots of representative tumors from each treatment group reflected the aforementioned mechanisms. Specifically, EZH2i increased the intratumoral level of H3K27ac. Introduction of BRD4 inhibitor caused a feedback activation of ERK signaling, which can be completely blocked by GDC-0994 ( Figure 6B ). Similar results were obtained in HCC PDX-0809, PDX-0309, and CDX SMMC-7721 models, in which triple-combination therapy significantly suppressed tumor growth and achieved TGI% 95.5%, 85.3%, and 74.3%, respectively ( Figures 6C, 6D , and S6B).
We also tested this combination in pancreatic and lung cancer. In pancreatic PDX-3527 tumor model, single treatment of EPZ-6438 had limited effects on tumor growth. Additional introduction of OTX015 and GDC-0994 significantly improved the efficacy (TGI%, 94.4%) ( Figure 6E T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T3   Vehicle  EPZ+OTX+GDC  GDC  EPZ+OTX  OTX  EPZ   T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T3   Vehicle  EPZ+OTX+GDC  GDC  EPZ+OTX  OTX  EPZ   T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T3   Vehicle  EPZ+OTX+GDC  GDC  EPZ+OTX (E) were treated with EZH2i (EPZ-6438), BRD4 inhibitor (OTX015), and Erk inhibitor (GDC-0994) alone or in indicated combinations at indicated dosages daily for indicated days. Intratumoral levels of H3K27me, H3K27ac, and other indicated proteins were detected by immunoblotting. Error bars represent mean ± SEM, n R 5 mice per group for (B) - (E) . (B)- (E) analyzed by unpaired two-tailed t test. *p < 0.05, **p < 0.01, ***p < 0.001. EPZ, EPZ-6438; OTX, OTX015; GDC, GDC-0994. See also Figure S6 and Table S7. (NCI-H23) models, in which combined therapy with EZH2, BRD4, and ERK1/2 inhibitors together achieved maximal tumor growth inhibition. The TGI% of triple combination was 114%, 82.8%, and 75.6%, respectively, suggesting a remarkable tumor growth inhibition ( Figures S6C-S6F) . None of these treatments had an overt systemic toxicity or a significant effect on the weight of the mice ( Figures S6G-S6N and Table S7 ).
Together, these data suggest that simultaneously targeting the MAPK signaling may provide a therapeutic option to further improve the efficacy of the epigenetic-based therapies, including HCC and pancreatic cancer, that lack effective clinical treatment.
DISCUSSION
Histone modifications are important epigenetic signatures that dictate gene expression states, cell identities in cancer, and the drug response to the treatment (Filippakopoulos and Knapp, 2014; Kim and Roberts, 2016) . In this study, we show that the intervention of a single epigenetic enzyme like EZH2 can regulate a set of epigenetic enzymes and thereby influence own-or orthoposition modifications. The secondary epigenetic effect could lead to a propagating wave in histone modifications and defines the ultimate histone modification pattern. A previous study has reported that the NSD2 activity change could affect numerous histone modifications (Jaffe et al., 2013) . We now report that EZH2i could lead to a global landscape change of histone marks. For instance, 45 histone marks were changed by more than 2-fold in our tested cell lines ( Figure 1A ). Among the globally altered histone marks, a specific interplay between H3K27me and H3K27ac was noted and shown to be critical for determining the drug response to the EZH2 inhibition, suggesting an intrinsic preference of histone modification crosstalk. For example, we have shown that H3K27me loss did not lead to a switch to other types of histone modifications occurring on the same residue, such as H3K27pr ( Figure 1A) , further supporting the existence of a distinct regulatory mechanism that specifically connects H3K27me loss to H3K27ac.
The H3K27me and H3K27ac crosstalk has been previously reported as an antagonistic switch on the same H3K27 residue in a small tumor subset-mostly hematological malignancies (Knutson et al., 2012; Lee et al., 2014; Pasini et al., 2010; Zhang et al., 2014) . We substantially extend earlier observations in cancer scope and mechanistically by showing that MLL1 forms a complex with p300 and facilitates p300-catalyzed H3K27ac upon PRC2 inhibition. Depletion of MLL1 fails to allow a switch from H3K27me to H3K27ac. All these collectively suggest an ''on-off'' switch for histone modifications that stringently requires MLL1.
MLL1 is generally believed to be present in multiple epigenetic complexes and is involved in the modification of various types of histone marks. MLL1 homolog was reported to be present in the TrxG complex that controls the on-off switch for gene transcription. A previous study suggested that MLL1 monomethylated histone H3K4 could promote H3K27ac (Tie et al., 2014) . Our findings advance this understanding by showing that the intrinsic presence of MLL1 functions as an adaptor protein complexed with p300 that directs H3K27me loss to the gain of H3K27ac modification, regardless of H3K4me status. The intrinsic MLL1 level varies between the different cancers (data not shown), which may largely explain the differential H3K27ac response despite the similar suppressed H3K27me.
ChIP-seq data showed that H3K27ac modified gene clusters were highly diversified among the different cell lines, with a preferential impact on oncogenes. This was further supported by the transcriptional outputs in different cell contexts, for example, Wnt/b-catenin and transforming growth factor b (TGF-b) in HCC cells and mTOR pathway and EGFR signaling in breast cancer cells (data not shown). BRD4 inhibition shut down the activated onco-pathways and re-sensitized cancer to EZH2i, demonstrating H3K27ac upregulation as a cause for the activation of the onco-pathways. All these data together indicate that H3K27ac-associated transcriptional output activates numerous onco-pathways and accounts for the resistance to EZH2i.
A previous work by De Raedt et al. (2014) has shown that loss of PRC2 function leads to RAS-MAPK signaling activation in subsets of malignant peripheral nerve sheath tumor (MPMST) with PRC2 (SUZ12/EED) loss and NF1 mutation. In our current study, the exploration of a broader cancer context allows us to obtain a more complete picture of RAS signaling activation upon loss of PRC2 function. At least three major scenarios exist. In some cells, like Pfeiffer cells, RAS/MAPK signaling is not increased upon EZH2i. U2932 cells represent another situation that echoes the findings by De Raedt in which Ras/MAPK signaling is activated via EZH2i-induced H3K27ac upregulation and inhibition of H3K27ac could block its activation. Apart from these two situations, there is another possibility that occurs more often in which the concurrent inhibition of H3K27ac with PRC2 could lead to a feedback activation of Ras/MAPK signaling via a different mechanism, such as the transcriptionally decreased ERK1. These findings provide an example that demonstrates the differential response of onco-pathways upon epigenetic modulation, highlighting the importance to carefully dissect the situation for the therapeutic benefit.
Together, the epigenetic interplay revealed in this study enabled us to expand the therapeutic potential of EZH2is from hematological malignances to solid tumors. In solid tumors, EZH2i-driven transcriptional changes are shown to be dispensable of H3K27me-regulated transcriptional network. Instead, MLL1/p300-dependent H3K27ac is essential to determine the ultimate and context-dependent transcriptional output. Of note, blockage of H3K27ac in this context could generate a cell-growth dependency to the MAPK pathway via transcriptional suppression of ERK1 ( Figure 7A ). These insights reveal that EZH2i caused the crosstalk between H3K27me and H3K27ac and leads to oncogene activation. This may suggest that targeting this crosstalk could provide therapeutic promise.
Accordingly, patients with EZH2 overexpression could be stratified into three subtypes for EZH2-based therapy, namely EZH2 mono-therapy, its combination with BRD4 inhibitors or p300 inhibitors, and a triple combination plus MAPK pathway inhibitors. In the clinical practice, a step-up combination guided by the intrinsic MLL1 expression and subsequent feedback activation of ERK is proposed ( Figure 7B ). Our findings provide a possible solution for proper patient stratification based on the MLL1-directed combination therapy for EZH2 aberrant patients that can be rapidly translated to clinical tests. The recent disappointing result of tazemetostat as mono-therapy in treating EZH2 mutant DLBCL patients (NCT01897571) also highlights the need for rational integration of combination therapy and concurrent development of biomarkers to identify possible responders, which may expand the translational avenue for EZH2is in cancer treatments.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and plasmids Cells were maintained in the appropriate culture medium suggested by suppliers. See Table S1 . Myc-MLL1 plasmid (Cat# RC215327) was purchased from OriGene Technologies. TCF/LEF1 luciferase reporter plasmid (Cat# GM-021042) was purchased from Genomeditech.
Patient-derived xenografts PDX-3527 model was established using tissue from a male Chinese pancreatic cancer patient undergoing surgery at Shanghai General Hospital. Informed consent was obtained from the patient and all procedures involving human samples were approved by the medical ethical committee. Tumor fragments were subsequently rinsed in saline and cut into small pieces of approximately 3 3 3 3 3 mm 3 . Tumor pieces were implanted subcutaneously on the right axilla of nude mice. After reaching generation 6 (P6), tumors were implanted subcutaneously on the right axilla of 4 -5 week old female nude mice to do the in vivo experiment. All animal experiments were performed according to the institutional ethical guidelines on animal care and were approved by the Institute Animal Care and Use Committee at Shanghai Institute of Materia Medica (No. 2017-04-DJ-27) . All the HCC PDX models (PDX-0055, PDX-0273, PDX-0309, PDX-0332, PDX-0512, PDX-0809 and PDX-0842) used were commercially available from WuXi AppTec. (http://onco.wuxiapptec.com/login). These models were generated from male Chinese patients with age from 47 to 74. Further detail regarding the identity of the human specimens used is not available. Primary tumor tissues were collected with the subject's informed consent for PDX establishment. In brief, surgically resected primary tumor tissues from patients were collected, trimmed, cut into 20 to 30 mm 3 fragments and immediately implanted subcutaneously by using an 18-gauge trocar in the fore and/or hind bilateral flanks of 6-to 8-week-old female NOD-SCID mice or BALB/c nude mice. Once the first generation of xenografts (designed as P0) was established and tumor sizes reached 500 to 800 mm 3 , serial implantations in BALB/c nude mice were performed to expand the xenograft tumors. All procedures and protocols were approved by the Institutional Animal Care and Use Committee at WuXi AppTec.
In Vivo tumor models CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) mouse models in this paper were listed in Table S7 . Cancer cells or patient tissue fragments were implanted subcutaneously on the right axilla of BALB/c nude or SCID female/male mice (4 to 8 weeks old) provided by Shanghai Laboratory Animal Center, Chinese Academy of Sciences, Shanghai SIPPR BK Laboratory Animals and Shanghai Lingchang Biotech (Table S7 ). The studies were conducted in compliance with the Institutional Animal Care and Use Committee guidelines of Shanghai Institute of Materia Medica. In addition, all the HCC PDX models were conducted by WuXi Pharma Tech in strict accordance with the Guide for the Care and Use of Laboratory Animals of the NIH. And BxPC-3 and NCI-H727 CDX models were conducted by PharmaLegacy Laboratories (Shanghai). All the procedures related to animal handling, care and the treatment in this part were performed according the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of Pharmalegacy following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALC).
METHOD DETAILS SILAC-based cell culture
The cells were grown in SILAC labeling medium. Roswell Park Memorial Institute medium 1640 (RPMI 1640) was supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 10% dialyzed Fetal Bovine Serum (FBS) and reconstituted separately with abundance analysis, cells cultured in heavy were treated with 1 mM EPZ-6438 for six days, whereas light cells were treated with DMSO as control. Cells were harvested by the treatment of 5% trypsin and washed three times with ice-cold Dulbecco's PBS.
Histone extraction and in-gel digestion
The heavy cells and light cells were mixed at 1:1 ratio and core histones were extracted by an acid-extraction method (Shechter et al., 2007) . Briefly, the cells were lysed with 3 volumes of extraction buffer (10 mM HEPES pH 7.0, 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 0.5% NP-40 and 1X protease inhibitor mixture). After centrifugation, the pellet was washed with extraction buffer without NP-40, and then resuspended in 0.2 M H 2 SO 4 overnight at 4 C. After centrifugation, the supernatant was collected for trichloroacetic acid-aided precipitation. The precipitate was then washed with chilled (À20 C) acetone containing 0.1% (v/v) HCl, followed by two times of wash with ice-cold 100% acetone. The precipitate was resolved by SDS-PAGE and visualized by Coomassie Brilliant Blue staining. Bands of histones (H2A, H2B, H3 and H4) were excised and cut into 1 mm 3 slices. Trypsin was used to digest histones at 37 C overnight and tryptic peptides were extracted for mass spectrometry.
Identification and quantification of histone modification sites All acquired MS raw files were transformed into MGF format by Proteome Discoverer software (version 1.4), and then all MGF files were analyzed by Mascot software (version 2.3.01) against a human histone sequence database (94 sequences, 14,024 residues) generated from the UniProt database (updated on 09/24/2014). Two groups of parameters were used to search for histone modifications as follows. 1) For light histone peptides,
, 2-Hydroxyisobutyrylaiton (K) and phosphoryl (STY) groups were specified as variable modifications. 2) For heavy histone peptides, Label:13(6)(K), Label: 13(6)(K)15N(4)R, Label:13(6)+ acetyl (K), Label:13(6)+methyl (KR), Label:13(6)+dimethyl (KR), Label:13(6)+trimethyl (K), Label:13(6)+propionyl (K), Label:13(6)+butyryl (K), Label:13(6)+malonyl (K), Label:13(6)+succinyl (K), Label:13(6)+crotonyl (K), Label:13(6)+ubiquitinyl (K), Label:13(6)+ADP ribosylation (K) and Label:13(6)+2-Hydroxyisobutyrylaiton (K) were specified as variable modifications. Other parameters for all analyses were specified as follows. Mass error was ± 10 ppm for parent ions and ± 0.5 Da for fragment ions. The enzyme was specified as trypsin with a maximum of 5 missed cleavages. Peptide ion score cutoff was 20, and the spectra of all identified peptides were checked manually according to the criteria reported previously to ensure the accuracy of peptide identification (Chen et al., 2005; Nie et al., 2017; Xie et al., 2012) . Identified peptides bearing modifications were manually quantified using the Xcalibur Qual Browser version 3.0.63. Extracted ion chromatograms were constructed for each precursor m/z value with a mass tolerance of 10 ppm and mass precision up to four decimal places. Peak areas for a pair of heavy and light peptides with the same retention time interval were calculated (Jung et al., 2010) . The SILAC ratios of unmodified peptides were used for the normalization of protein expression level. Two technical replicates were performed for each cell line (U2932, SMMC-7721, T47D, SU-DHL-4, KARPAS-422, Pfeiffer). Student t test was used to determine the significant change of histone marks. At least 2-fold change and p value < 0.05 were considered significant difference.
Sample preparation for Tandem Mass Tag labeling
Cells were DMSO control-treated or treated with EPZ-6438 for 6 days. Cells were harvested by the treatment of 5% trypsin, washed three times with ice-cold Dulbecco's PBS, collected in chilled lysis buffer (8.0 M urea in two parts 0.1 M NH 4 HCO 3 and one part 0.1 M NaHCO 3 (v/v) with 1x protease inhibitor and 1x phosphatase inhibitor), and incubated on ice for half an hour. The lysate was centrifuged at 20,000 g for 5 min at 4 C. The supernatant was transferred to another tube and the protein concentration was determined by BCA (bicinchoninic acid) assay. Dithiothreitol was added to the protein solution (200 mg protein) to a final concentration of 5 mM and then the lysate was incubated at 56 C for 30 min, followed by incubation with 15 mM iodoacetamide in the darkness for 30 min at room temperature. The alkylation reaction was quenched with 30 mM cysteine at room temperature for another 30 min. The protein solution was subjected to a 4-fold dilution with 100 mM NH 4 HCO 3 (pH 8.0) and then treated with sequencing grade trypsin at a trypsin-to-protein ratio of 1:50 (w/w) at 37 C for 16 h. Trypsin was then added at trypsin-to-protein ratio of 1:100 (w/ w) at 37 C for another 4 h to complete the digestion cycle. The tryptic peptides were desalted through SepPak C18 cartridges and vacuum-dried before TMT labeling.
TMT labeling, basic reverse-phase fractionation and mass spectrometry analysis TMT labeling was performed as previously described (Paulo et al., 2015a) . For each condition, 50 mg peptides were labeled with the TMT reagents. DMSO control samples were labeled with 126, 128, and 130; EPZ-6438-treated samples were labeled with 127, 129, and 131. Following incubation at room temperature for 1 h, the reaction was quenched with hydroxylamine to a final concentration of 0.5% (v/v). The labeling efficiency for the peptides was > 97%, as determined by differential TMT modification. The TMT-labeled samples were pooled at a 1:1 ratio across all samples and subsequently vacuum-centrifuged to near dryness and subjected to Sep-Pak C18 desalting.
TMT-labeled peptides (300 mg) were separated by high pH reverse-phase HPLC using Waters XBridge Peptide BEH C18 column (130 Å , 5mm, 4.6 3 250 mm, Waters, Milford, MA) using a 90-min gradient from 2% to 95% of buffer (10 mM ammonium formate/80% ACN, pH 8.5) at a flow rate of 1 mL/min. The sample was collected into 80 fractions, combined into 20 fractions, and vacuum-dried for mass spectrometric analysis.
The dried peptide samples were dissolved in buffer (0.1% formic acid in water, v/v). Each fraction was analyzed on an Orbitrap Fusion (Thermo Scientific) running a 70-min gradient from 8% to 45% acetonitrile using a MS2-based method. The Automatic Gain Control (AGC) targets were 500,000 for full scan with the maximum injection time of 50 ms and 500,000 for MS/MS scan with the maximum injection time of 80 ms in the Orbitrap, respectively. Survey full-scan MS spectra (from m/z 450 to 1500) were acquired in the Orbitrap with resolution R = 60,000 at m/z 200, followed by MS/MS fragmentation of top 15 most intensive ions with high collision dissociation (HCD) energy of 40% with resolution R = 15,000 at m/z 200.
TMT-labeled phosphorylated peptides were enriched using TiO 2 as previously described (Paulo and Gygi, 2015; Paulo et al., 2015b) . Briefly, 1 mg 6-plex TMT-labeled peptides were resuspended in loading buffer (6% TFA, 80% ACN, 1 M lactic acid), and then incubated with titanium dioxide beads (GL Sciences, Japan) for 30 min at room temperature. Beads were washed with loading buffer and washing buffer (0.5% TFA, 50% ACN). Enriched phosphorylated peptides were eluted with 15% NH 3 $H 2 O and vacuumcentrifuged to dryness.
The dried phosphorylated peptide samples were desalted and then dissolved in buffer A (0.1% formic acid in water, v/v). Each fraction was analyzed on an Orbitrap Fusion running a 110-min gradient from 2% to 36% acetonitrile using a MS2-based method. The AGC targets were 500,000 for full scan with the maximum injection time of 50 ms and 500,000 for MS/ MS scan with the maximum injection time of 80 ms in the Orbitrap, respectively. Survey full-scan MS spectra (from m/z 350 to 1500) were acquired in the Orbitrap with resolution R = 60,000 at m/z 200, followed by MS/MS fragmentation of top 15 most intensive ions with high collision dissociation (HCD) energy of 40% with resolution R = 15,000 at m/z 200.
Cell viability assay
Cells were seeded in 96-well plates overnight and treated with indicated compounds. SRB or CCK8 assay (Life Technologies) was carried out after incubation for 6 days. The absorbance (optical density, OD) was read at a wavelength of 450 nm for CCK8 and 515 or 560 nm for SRB on an ELISA plate reader. The IC 50 values were calculated by concentration-response curve fitting using the four-parameter method.
Immunoblotting analysis
For immunoblotting, cells were lysed using preheated 2% SDS followed by boiling for 30 min. Protein concentrations were determined using a BCA assay (Thermo Scientific). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (General Electric). Membranes were blocked for 1 hr at room temperature with 5% milk in 1xTris-buffered saline Tween-20 (TBST) (25 mM Tris, 150 mM NaCl, 2 mM KCl, pH 7.4, supplemented with 0.2% Tween-20) and probed with the indicated primary antibodies at 4 overnight. After washing with TBST three times for 30 min, membranes were incubated with peroxidase-conjugated secondary antibodies at room temperature for 1 hr. The membranes were washed with TBST three times and visualized with chemiluminescence (Thermo Scientific). Representative blots are shown from several experiments. Band intensities in Figure 1C , Figure 2E , Figure 3K were quantified by ImageJ and were normalized using either b-actin, GAPDH or Histone H3 as housekeeping protein.
(Co-immunoprecipitation) Co-IP experiments were performed as follows: cells were lysed in lysis buffer (NP-40, 1 3 protease inhibitor cocktail (Roche) and phosphatase inhibitors (Roche)) for 30 min on ice. Crude lysates were subjected to centrifugation at 12, 000 x g for 15 min at 4 C. Supernatants were incubated with the appropriate antibodies (such as p300, Active Motif) with rocking for 12 hr at 4 C. Protein A/G Magnetic Beads (Thermo Fisher, #88802) was added, followed by rocking for 6 hr at 4 C. The beads were washed three times with lysis buffer. Proteins were eluted by boiling in 1 3 SDS running buffer and subjected to SDS-PAGE for immunoblotting.
RNA isolation and RT-qPCR analysis RNA from cell lines was isolated using Trizol extraction (Invitrogen). cDNA was prepared using HiScript II 1st Strand cDNA Synthesis Kit (+gDNA wiper) (Vazyme). RT-qPCR was performed following the instruction for ChamQ SYBR qPCR Master Mix (Vazyme) with V7 Real-Time PCR system (Applied Biosystems). Expressed values relative to control were calculated using the DDCT method. b-actin was used as a housekeeping gene for normalization. Results were represented as fold expression. The sequences of primers used for qPCR analysis were listed as follows.
Primers
Oligonucleotide ( ChIP-seq and ChIP-qPCR H3K27ac ChIP-seq data was generated by Active Motif's Epigenetic Services team. U2932, SMMC-7721 and Pfeiffer cells plated in 10 cm dishes were untreated with DMSO or 1 mM EPZ-6438 for 6 days respectively. Then cells were fixed with 1% formaldehyde for 10 min at room temperature. To stop the reaction, glycine was added to a final concentration of 0.125 M at room temperature for 5 min. Cells were collected by scraping or centrifuge and transferred with contents of each dish to a 50 mL tube. Samples were keeping on ice for the remainder of the procedure. Centrifuge tubes at 800 x g in a refrigerated centrifuge for 10 min to pellet the cells. Fixed cells were washed 2 times with 10 mL chilled PBS-1%NP40 and washed with 10 mL chilled PBS-1%NP40-PMSF (PMSF final concentration will be 1 mM) finally. Cell pellets were snap-freezed in liquid nitrogen for 10 min, stored at À80 C and then shipped to Active Motif on dry ice for H3K27ac ChIP-seq assay.
ChIP-qPCR assay was performed using SimpleChIP Plus Enzymatic Chromatin IP Kit (Magnetic Beads) (Cell Signaling Technology, #9005) according to the procedures provided by the manufacturer. Antibodies used for ChIP were as follows: anti-immunoglobulin G (Cell Signaling Technology, #2729), anti-Histone H3 (Cell Signaling Technology, #4620), anti-Histone H3K27me3 (Cell Signaling Technology, #9733), anti-Histone H3K27ac (Active Motif, #39133), anti-p300 (Active Motif, #61401), and anti-MLL1 (Cell Signaling Technology, #14197). The final ChIP DNAs were then used as templates in qPCR reactions, using primers that encompass genes' promoter region. The sequences of the primers were as follows:
Luciferase reporter assay Cells pretreated with 1 mM EPZ-6438 for 4 days were transfected with the TCF luciferase reporter plasmid using Lipofectamine 2000 Reagent Agent (Life Technologies, #11668019) for 48 hr. Luciferase activity was analyzed using Dual-Luciferase Reporter Assay System (Promega, #E1960). Data were normalized to Renilla luciferase activity. 
Clonogenic assay
Cells were seeded into 6-well plates at a concentration of 500-1000 cells per well. After 24 hr, cells were treated with indicated compounds for about 2 weeks. Colonies were fixed with fixation solution (10% methanol + 10% acetic acid) at room temperature for 15 min and then stained with a solution of 1% crystal violet in methanol for 15 min.
siRNA transfections
For siRNA transfection, cells were plated at about 40% confluence in OPTI-MEM serum-free medium and transfected with a specific siRNA duplex using Lipofectamine RNAiMAX Reagent Agent (Life Technologies, #13778-150) according to the manufacturer's instructions for 48 hr. For suspension cells, such as U2932, electrotransfection was conducted at 180V by BIO-RAD Gene Pulser Xcell Electroporation System. siRNAs were ordered as RPHPLC-purified duplexes from GenePharma. The sequences of the siRNAs used in this study are shown as follows.
RNA-seq RNA-seq data was generated by Novogene. U2932, SMMC-7721 and Pfeiffer cells plated in 10 cm dishes were treated with DMSO or 1 mM EPZ-6438 for 6 days respectively. Then cells were washed by PBS for 3 times and then lysed by Trizol at room temperature. Samples were sent to Novogene on dry ice. A total amount of 3 mg RNA per sample was used as input material for the RNA sample preparations. Sequencing libraries were generated using NEBNext UltraTM RNA Library Prep it for Illumina (NEB, USA) following manufacturer's recommendations and index codes were added to attribute sequences to each sample. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3-cBot-HS (Illumia) according to the manufacturer's instructions. After cluster generation, the library preparations were sequenced on an Illumina platform and 125 bp/150 bp paired-end reads were generated. GSEA was used for cellular pathway analysis.
Immunohistochemistry
Tumors fixed by 4% Paraformaldehyde were embedded by paraffin. IHC assay were performed by Shanghai ZuoChengBio. EZH2 1:100 (Cell Signaling Technology, #9005) and MLL1 1:200 (Cell Signaling Technology, #14197)
Combination therapy and criteria for synergism in vitro The combination therapies were performed in 96-well plates as described above (cell viability assay). Cells were treated with EPZ-6438, JQ1 or combination at gradient concentrations for 6 days and cell growth was measured by SRB or CCK-8 assay. To determine the presence of a possible synergistic effect, the combination index (CI) was calculated by by CalcuSyn Demo Version 2.0 software. A combination index CI < 0.8 indicates synergism and CI > 1.2 an antagonistic effect.
Drug treatment in vivo
Established PDX and CDX models were used for drug treatment. All experiments were performed according to the institutional ethical guidelines on animal care and approved by the Institute Animal Care and Use Committee at Shanghai Institute of Materia Medica, WuXi AppTec, and Green Valley. Tumorbearing mice were randomized into groups and started dosing when average tumor volume reached 50-100 mm 3 . EPZ-6438 (200 mg/kg, 0.5%CMCNa + 0.1%Tween80 + ddH 2 O), OTX015 (50-70 mg/kg, 1%DMSO + 30% PEG300 + 1%Tween80 + ddH 2 O) and GDC-0994 (15-50 mg/kg, 0.5%CMCNa + 0.1%Tween80 + ddH 2 O) were given orally daily and JQ1 (30-80 mg/kg, 1%DMSO + 5%Glucose + ddH 2 O) i.p. daily for the number of days indicated. For combination treatment, drugs were given concurrently. Tumor growth was monitored by the measurement of tumor size using calipers twice or three times per week using the formula (length 3 width 3 width)/2. Body weight was measured twice or three times per week. Mice were euthanized and tumor tissues collected 6 hr after the last dosing and prepared for immunoblotting or immunohistochemistry staining. For systematical toxicity analysis, blood sample (500-800 mL) was taken 6 hours after the final dose via cardiac puncture with EDTA-2K as anticoagulant (500-800 mL whole blood into 5 ul 0.5M EDTA-2K). Hematological markers and Clinical biochemistry were measured. The individual relative tumor volume (RTV) was calculated as follows: RTV = V t /V 0 , where V t is the volume on each day and V 0 is the volume at the beginning of the treatment. TGI rate was measured using the formula: TGI (%) = [1 -(V t -V 0 in treated group)/(V t -V 0 in vehicle group)] 3 100
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
Statistical analysis was performed using GraphPad Prism software (version 5.0). All data are presented as mean ± SEM. Analysis of two samples was performed with unpaired two-tailed Student t test for equal variance, or t test with Welch's correction for heterogeneity of variance ( Figures 2F, 3H , 3J, 4B-4D, 5E-5F, 6B-6E, S2C, S2D, S2H, S3F, S4A, S4B, and S6B-S6E). One way ANOVA with Dunnnett's multiple comparisons test was used in Figures S1C and S1E. In Table S6 , fold enrichment values represent the mean of three biological repeats. The significance of fold enrichment was calculated using a BH adjusted p value. Differences were considered statistically significant when the p values were less than 0.05.
Proteomic and phosphoproteomic data analysis
All raw data files were searched against the human database from Uniprot (updated on 09/29/2015) with MaxQuant (1.5.3.8) with a FDR of < 1% at the level of proteins, peptides and modifications. Enzyme specificity was set to trypsin, allowing for cleavage N-terminal to proline. For proteomic data analysis, acetyl (Protein N-term) and oxidation (M) were set as variable modifications.
For phosphoproteomic data analysis, acetyl (Protein N-term), oxidation (M) and phosphoryl (STY) were set as variable modifications. The TMT label on lysine residues and peptide N-termini (+229.163 Da) and carbamidomethylation of cysteine residues (+57.021 Da) were set as fixed modifications. Up to two missed cleavages were permitted and the minimum required peptides length was seven amino acids. To quantify phosphosites that were up-or downregulated in response to EPZ-6438 or JQ1 treatment, the intensities of the replicates were normalized by median-centering (i.e., setting the median ratio equal to one) and the treated/control ratio was calculated for each replicate. Phosphorylation events with a localization probability above 0.75 were considered localized on the respective S/T/Y residue. Phosphopeptides with a Benjamini-Hochberg (BH) adjusted p value < 0.05 in each biological replicate were defined as significantly regulated. Average ratios from the biological repeats and the corresponding p value were visualized with volcano plots and fold change of > 1.5 was chosen as the significance cutoff.
KEGG pathway analysis DAVID bioinformatics functional annotation tool was used to identify enriched KEGG pathway terms. The significance of fold enrichment was calculated using a BH adjusted p value < 0.05. (https://david.ncifcrf.gov/).
Oncogenic signature enrichment analysis GSEA (gene set enrichment analysis) was performed using gene set collections ''c6'' (oncogenic signatures) from the MSigDB as bioinformatics functional annotation tool. For H3K27ac ChIP-seq data analysis, single sample GSEA analysis of the genes and promoter peak number differences were used in three cell lines (SMMC7721, U2932 and Pfeiffer) (Mertins et al., 2016) . These ChIP-seq signatures were then used in a pre-rank-based single sample GSEA test to determine their enrichment in promoter peak number differences data treated by EPZ-6438. For RNA-seq data analysis, raw data were normalized in three replicates for GSEA analysis. The EPZ-6438-treated over DMSO-treated sample signal2noise data were used to determine RNA-seq enrichment pathways. The proteomics data were filtered to remove proteins with missing values and combined by using the median normalization to get ratio with EPZ-6438 treatment (or EPZ-6438-JQ1 combo) compared with DMSO. These proteo-signatures were then used in a pre-rank-based GSEA test to determine their enrichment in EPZ-6438-treated (or EPZ-6438-JQ1 combo) over DMSO-treated sample ratio data. A heatmap of all pathways tested is shown in Figure 3A . Enrichment of selected oncogenic pathways in H3K27ac ChIP-seq, RNA-seq and proteome are shown in Figure S3A . The enriched oncogenic pathways of proteome after EPZ-6438 treatment and EPZ-6438-JQ1 co-treatment are shown in Figure 5A . The R package ''gplots'' was used for plotting.
DATA AND SOFTWARE AVAILABILITY
All mass spectrometry raw data have been deposited to the iProX, a full member of the ProteomeXchange consortium (Dataset ID: IPX0001297000). The sequence data reported in this paper have been deposited in the NCBI through GEO Series accession number: GSE119086 for ChIP-seq data and GSE119088 for RNA-seq data. IC50 ( Histone H3 Vehicle  GSK126  EPZ   T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4   U2932   H3K27ac   H3K27me3 Histone H3
(legend on next page) (B) . H3K27ac was detected by immunoblotting. Error bars represent mean ± SEM, n = 3 replicates for (C) and n = 6-12 mice for (E) . (C) and (E) analyzed by one-way ANOVA with a Dunnett's multiple comparisons test. ***p < 0.001. ''EPZ'' represents EPZ-6438. (E) Histone H3K27 acetylation, MLL1 and p300 accumulation in WNT11, TGM2 and NPC1L1 promoters. SMMC-7721 cells were treated with EPZ-6438 (1 mM) for 6 days before being subjected to ChIP assay using anti-acetyl-histone H3K27 (H3K27ac), MLL1 or p300 antibodies respectively followed by qRT-PCR analysis using primers targeting indicated WNT11, TGM2 and NPC1L1 promoter region. n R 2 replicates. (F) Histone H3K27 acetylation and tri-methylation in CTNNB1 promoter. SMMC-7721 cells were treated with EPZ-6438 (1 mM) for 6 days before being subjected to ChIP assay using anti-acetyl-histone H3K27 (H3K27ac) or anti-tri-methyl-histone H3K27 (H3K27me3) antibody followed by qRT-PCR analysis using primers targeting indicated CTNNB1 promoter region. n R 2 replicates. (G) CTNNB1 protein level change. Cells were transfected with non-targeting control (NC) or EZH2-siRNAs for 6 days. Protein levels were detected by immunoblotting.
Error bars represent mean ± SEM (E) and (F) analyzed by unpaired two-tailed t test. *p < 0.05, **p < 0.01, ***p < 0.001. NES, normalized enrichment score; P, nominal p value; Q, FDR q value. ''EPZ'' represents EPZ-6438. U2932 and SU-DHL-5 cells were treated with EPZ-6438 (10 mM) and JQ1 (1 mM) alone or in indicated combinations for 6 days. Cell growth change was measured by counting cell numbers. Other cells were treated with EPZ-6438 (1 mM) and JQ1 alone or in combination for about 2 weeks and cell growth change was measured by colony-formation assay. (B) Synergistic anti-cancer efficacy in vivo. Mice were treated with EPZ-6438 (200 mg/kg) and BRD4 inhibitor (JQ1 or OTX015) alone or in combination daily for indicated days. (C) The difference of EZH2 and MLL1 expression level among CDX and PDX models by IHC. Scale bar, 50 mM Error bars represent mean ± SEM, n R 2 replicates for (A) and n = 6-12 mice per group for (B) . (A) and (B) analyzed by unpaired two-tailed t test. *p < 0.05, **p < 0.01, ***p < 0.001. ''EPZ'' represents EPZ-6438 Figure S5 . Inhibition of MAPK Signaling Improves the Therapeutic Potential of Epigenetic Targeted Combination Therapy, Related to Figure 5 (A) The volcano plot illustrates the fold changes of phosphosites in co-treatment of EPZ-6438 and JQ1 in SMMC-7721 and U2932 cells compared with DMSO treated cells. The corresponding adjusted p values were calculated in three biological replicates. The upregulated phosphosites were shown in red, the downregulated phosphosites were shown in blue and the statistically insignificant phosphosites were shown in gray. (B) A scheme showing the affected phosphosites in the MAPK pathway by the treatment of EPZ-6438 and JQ1 in SMMC-7721 and U2932 cells. SMMC-7721 or U2932 cells pretreated with EPZ-6438 (2 mM) for 3 days were exposed to EPZ-6438 (2 mM) and JQ1 (0.5 mM) for 3 extra days followed by MS analysis. Phosphosite change was analyzed by MaxQuant and normalized to protein expression level. Red, upregulated phosphosites. Blue, downregulated phosphosites. (C-D) The altered phosphoproteome interaction networks by co-treatment of EPZ-6438 and JQ1 using STRING database with high confidence (combined_score > 0.7) and visualized by Cytoscape. The interaction network was subjected to a cluster analysis using the algorithm MCODE based on the protein interaction level. Clusters are represented with different colors. Each cluster was manually annotated based on KEGG pathway enrichment analysis. (E) Erk and RSK phosphorylation change. Cells treated with GSK126 (1 mM) for 3 days Erk and RSK activation were examined by immunoblotting. H3K27ac   T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T3   Vehicle  EPZ+JQ1+GDC  GDC  EPZ+JQ1  JQ1  EPZ   T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T3   Vehicle  EPZ+OTX+GDC  GDC  EPZ+OTX  OTX  EPZ   T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T3   Vehicle  EPZ+OTX+GDC  GDC  EPZ+OTX  OTX  EPZ   p-RSK1  RSK1   H3K27me3   GAPDH   Histone H3   H3K27ac   T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T1 T2 T3   Vehicle  EPZ+JQ1+GDC  GDC  EPZ+JQ1  JQ1 (legend continued on next page)
